|Population-Level Incidence and Risk Factors for Pulmonary Toxicity Associated With Amiodarone Cynthia Anne Jackevicius, BScPhm, PharmD, MSca,b,c,d, Albert Tom, PharmDa, Vidal Essebag, MD, PhDe, Mark J. Eisenberg, MD, MPHe, Elham Rahme, PhDe, Jack Ven Tu, MD, PhDb,c, Karin Humphries, MBA, DScf, Hassan Behlouli, PhDe, and Louise Pilote, MD, MPH, PhDe,*
Enantioselective Heck Reactions with Aryldiazonium Salts. Challenges and Synthetic Opportunities Caio Costa Oliveira, Ricardo Almir Angnes, Cristiane Storck Schwalm, Carlos Roque Duarte Chemistry Institute – State University of Campinas, São Paulo – Brazil Enantioselective catalysis has revolutionized the field of organic synthesis and has brought significant scientific and economic benefits for our society. The enantioselective arylation of olefins in particular (Heck reaction) has been a subject of intense academic and industrial interest due to its potential for providing enantiomeric enriched medicines, fragrances and new materials, which are in general more selective and less toxic than the racemic counterpart. In this context, the Pd-catalyzed coupling of arenediazonium salts to olefins (Heck-Matsuda reaction) stands as a more practical and reliable method to access structurally complex organic molecules than the conventional Heck protocols. The Heck-Matsuda arylations can be easily performed in the lab under aerobic conditions without requiring expensive and/or toxic phosphine ligands. The first examples of these reactions were described by Tsutomu Matsuda in 1977. However, in spite of the many advantages and the long-term existence of this reaction, its enantioselective version has, until recently, constituted a considerable challenge due to the intrinsic incompatibility between the ordinary phosphine ligands and the arenediazonium salts. In this lecture, the first examples of effective enantioselective Heck-Matsuda reactions will be presented using chiral bisoxazoline ligands.1 Some recent developments from our lab will also be highlighted.
Les risques du tabagisme REMERCIEMENTSCette brochure a été réalisée avec le concours Tél : 01 45 59 59 59 du Dr Anne Borgne, responsable de l'unité La dépendance au tabac d'addictologie de l'hôpital Jean Verdier (Bondy). site internet : www.arc.asso.fr Les bénéfices de l'arrêt Siret : 785 789 454 000 36 Illustrations : Eric Sault / ARC Adresse Postale :
Deaths from Marijuana v. 17 FDA-Approved Drugs (Jan. 1, 1997 to June 30, 2005) http://medicalmarijuana.procon.org/view.resource.php?resourceID=000145 I. Background Much of the medical marijuana discussion has focused on the safety of marijuana compared to the safety of FDA-approved drugs. On June 24, 2005 ProCon.orto the US (FDA) to find the number of deaths caused by marijuana compared to the number of deaths caused by 17 FDA-approved drugs. Twelve of these FDA-approved drugs were chosen because they are commonly prescribed in place of medical marijuana, while the remaining five FDA-approved drugs were randomly selected because they are widely used and recognized by the general public.
Send Orders for Reprints to [email protected] Letters in Drug Design & Discovery, 2015, 12, 93-102 Quantum-chemical Study on the Thermodynamical Aspect of Competitive Inhibition of Ribonucleotide Reductase by trans-Resveratrol, trans-Piceatannol and Hydroxyurea
Order Code IB88090 CRS Issue Brief for Congress Received through the CRS Web Nuclear Energy Policy Updated June 4, 2003 Mark Holt and Carl E. Behrens Resources, Science, and Industry Division Congressional Research Service ˜ The Library of Congress MOST RECENT DEVELOPMENTS BACKGROUND AND ANALYSIS Overview of Nuclear Power in the United States